Fresenius lifts 2026 expectations after strong Q3
Fresenius raised its expected EBIT margin to above 11.5% and said 2026 constant-currency core EPS growth should be at the upper end of its 10%-15% range. Third-quarter EBIT was €638 million, above the €618.5 million consensus.
1. Raised expectations
Fresenius lifted its full-year expectations after stronger-than-anticipated third-quarter results, marking its second guidance upgrade this year. The company now expects an EBIT margin above 11.5%, compared with around 11.5% previously, and 2026 constant-currency core EPS growth at the upper end of its 10%-15% range.
2. Division results
Third-quarter EBIT before special items was €638 million, exceeding the €618.5 million consensus. Kabi generated €391 million in EBIT, slightly above consensus, while Helios reported €293 million, 6% above expectations, with the company citing efficiency measures and improving profitability in Germany and Spain.
3. Medical care contrast
The results contrasted with those of former unit Fresenius Medical Care, in which Fresenius retains a 25% stake. The dialysis specialist cut its operating income outlook after a third consecutive quarterly decline in U.S. treatment volumes.
